$70.11
-11.44-14.03%
Last update: Oct 30, 7:28 PM
10x Genomics Inc
TXGNASDAQ
10x Genomics (TXG) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
10x Genomics (TXG) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided revenue in the range of $610M - $630M for the period.
Compared to prior guidance, 10x Genomics raised its revenue forecast from a prior range of $600M - $625M.
10x Genomics has issued 22 guidance updates between November 2, 2022 and August 6, 2026. During this period, the company raised its outlook 13 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.06 | $-0.10 | $-0.10 | $-0.15 |
| Actual | $-0.14 | $-0.10 | $-0.13 | $-0.22 |
| Surprise | -133.3% | 0.00% | -30.0% | -46.7% |
| Revenue | ||||
| Estimate | $146.7M | $146.4M | $159.1M | $142.5M |
| Actual | $151.0M | $150.8M | $166.0M | $149.0M |
| Surprise | +2.95% | +3.05% | +4.34% | +4.59% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.07 | $-0.04 | $-0.07 | $-0.11 |
| Revenue | ||||
| Consensus | $147.7M | $171.4M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.14 | $-0.06 | -133.3 % |
| Q1 | May 7, 2026 | $-0.10 | $-0.10 | 0.00 % |
| Q4 | Feb 12, 2026 | $-0.13 | $-0.10 | -30.0 % |
| Q3 | Nov 6, 2025 | $-0.22 | $-0.15 | -46.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $151.00M | $146.68M | 2.95 % |
| Q1 | May 7, 2026 | $150.84M | $146.38M | 3.05 % |
| Q4 | Feb 12, 2026 | $166.03M | $159.13M | 4.34 % |
| Q3 | Nov 6, 2025 | $149.00M | $142.47M | 4.59 % |
